Pharmaceutical Industry Representatives Research Articles

"C" is for costs, and cancer, and conference: Highlights of the First European Conference on the Economics of Cancer

The first European conference on the economics of cancer was held in Brussels, Belgium on November 19-21, 1997. This international meeting was organized under the European Organization for Research and Treat ment of Cancer. Approximately 300 participants from around the world, including physicians, health care econ omists, epidemiologists, pharmaceutical industry repre sentatives, pharmacists, and other researchers, clinicians, and administrators attended the sessions. This interna tional mix of professions, along with the 12 plenary sessions, 4 tutorials, and over 100 contributed oral and poster presentations, made for a very interesting and informative conference. This review will focus on out comes measurement tools, pharmacoeconomics in clini cal trials, issues regarding the improvement of the quality and usability of pharmacoeconomic evaluations, and state of the art pharmacoeconomic reviews of hematopoietic growth factors and lung cancer. Abstracts of contributed presentations have already been published.1

Activities of Pharmaceutical Industry Representatives at a Major Teaching Hospital

Activities of Pharmaceutical Industry Representatives at a Major Teaching Hospital

Medication use and the elderly: current status and opportunities.

The crucial role played by medication use in the elderly is common knowledge in the worlds of health services research, clinical epidemiology, and geriatrics. It is now widely known that although persons over age sixty-five represent only about 13 percent of the population, they consume nearly one-third of all medications in the United States; that medications probably are the single most important health care technology in preventing illness, disability, and death in the geriatric population; that drugs represent one of the largest and fastest-rising out-of-pocket health care expenditures for the elderly; and that the old, because of their high drug usage rate, greater frequency of coexisting illnesses, and diminished physiological reserves, are at greater risk of experiencing adverse drug effects. Yet despite this knowledge, the use of drugs by the elderly and their clinical outcomes have not been prominent research or programmatic priorities for federal government, philanthropic, or corporate grantmakers. Beginning in the mid-1980s, The John A. Hartford Foundation began a grant-making program in the area of medication use and aging, out of an interest in enhancing the therapeutic effect of drugs used by this age group and in reducing the frequency and consequences of adverse drug events. After a number of years of active support in this area, the foundation convened its Expert Panel on Medications and Aging. This panel brought together authorities in the disciplines of geriatrics, gerontology, epidemiology, health services research, public policy, and pharmacology. Its mandate was to provide a consensus report that would critically define the further work needed to make the use of medications by the elderly more effective. This essay represents a synthesis of the work of that panel. The positions and opinions expressed below are extracted from transcripts of the expert panel’s deliberations, a structured survey administered to panel members,

Defining the Role of Pharmaceutical Industry Representatives

Defining the Role of Pharmaceutical Industry Representatives